Disease modifying therapies for patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Back

ESC2025 Premium Access

Disease modifying therapies for patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Session: New perspectives in cardiology (1) - Cardiac amyloidosis (1)

Topic: Infiltrative Myocardial Disease

Speaker: Doctor P. Soltani (Tehran, IR)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Parnian Soltani

Tehran Heart Center, Tehran University of Medical Sciences, Tehran (Iran (Islamic Republic of))

0 follower

10 more presentations in this session

Discussant - Cardiac amyloidosis (1)

Access

The role of nutritional status, measured by serum albumin, as a prognostic factor in wild-type transthyretin amyloidosis

Speaker: Mr S. Decotto (Buenos Aires, AR)

Clinical characteristics and follow-up outcomes of patients with wild-type transthyretin amyloidosis: comparison of the pre- and post-bone scintigraphy eras in a Latin American center.

Speaker: Miss P. Domenech (Buenos Aires, AR)

Wild-type transthyretin cardiac amyloidosis: sex differences in prevalence, phenotype, and prognosis

Speaker: Assistant Professor A. Zaroui (Creteil, FR)

Predictors of major adverse cardiovascular events in patients with wild-type transthyretin amyloid cardiomyopathy: insights from a regional hospital experience

Speaker: Doctor A. Martins (Leiria, PT)

Access the full session

New perspectives in cardiology (1) - Cardiac amyloidosis (1)

Speakers: Doctor P. Soltani, Mr S. Decotto, Miss P. Domenech, Assistant Professor A. Zaroui, Doctor A. Martins

Access

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources